Back to Results

Cell MedX Corp (STME)

Cell MedX Corp, formerly known as StimCell Energetics Inc., is a common stock listing on OTC Markets in the healthcare sector. The company, incorporated in 2010 and headquartered in Vancouver, Canada, is associated with a biotech business focused on developing, manufacturing, and commercializing therapeutic and non-therapeutic products. Its stated areas of interest include diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney-related functions in the United States. The company’s product line includes the eBalance Pro System for use by healthcare practitioners in clinical settings and the eBalance Home System for home use, both designed around the eBalance Console and its pre-programmed microcurrent algorithms for wellness, pain management, and dual use. The systems are also described as providing temporary relief for pain in the shoulder, waist, back, neck, arms, and legs.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-STME
$0.26
-4.6% Downside
Fair
—
—
—
Weak
—
—
—
0.0%
August 28, 2026
-6.6x
-3.5x
—
5.835 M
6.594 M
11.6%
27.9%
-1,578.4
—
36.9%
Valuation • Fair Value

Cell MedX Corp (OTC-STME) Fair Value by Valuation Model

Compare the primary fair value estimate for Cell MedX Corp (OTC-STME) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.26

Estimated downside of 4.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.23

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.27

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Cell MedX Corp (OTC-STME) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Cell MedX Corp (OTC-STME)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Cell MedX Corp (OTC-STME) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cell MedX Corp (OTC-STME)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-1,578.4

Lower score that deserves closer risk review.

FCF / Net Income

36.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cell MedX Corp (OTC-STME). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cell MedX Corp (OTC-STME)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 28, 2026

Days to Earnings

38

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Cell MedX Corp (OTC-STME), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cell MedX Corp (OTC-STME) Stock Forecast & Technical Outlook

Review Cell MedX Corp (OTC-STME) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cell MedX Corp (OTC-STME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cell MedX Corp (OTC-STME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Cell MedX Corp (OTC-STME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Cell MedX Corp (OTC-STME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Cell MedX Corp (OTC-STME) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cell MedX Corp (OTC-STME)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Cell MedX Corp (OTC-STME) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Cell MedX Corp (OTC-STME) Stock FAQ

Quick answers about Cell MedX Corp (OTC-STME) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.26
Estimated downside 4.6%
Valuation Rating
Overvalued
Estimated downside of 4.6%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Cell MedX Corp (OTC-STME) is $0.26. This implies an estimated downside of 4.6% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 4.6% versus the current market price.

An analyst price target for Cell MedX Corp (OTC-STME) is not currently available in the latest data file.

The current financial health read for Cell MedX Corp (OTC-STME) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cell MedX Corp (OTC-STME) is August 28, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Cell MedX Corp (OTC-STME) is -6.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Cell MedX Corp is 5.835 M.

The current enterprise value listed for Cell MedX Corp is 6.594 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cell MedX Corp is OTC-STME, and the stock is listed on OTC Markets.

Cell MedX Corp (OTC-STME) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Cell MedX Corp is 11.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cell MedX Corp is 27.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on OTC Markets View more

Essilor International SA (ESLOY) Essilor International SA (ESLOY)
Hoya Corp (HOCPY) Hoya Corp (HOCPY)
Siemens Healthineers AG ADR (SMMNY) Siemens Healthineers AG ADR (SMMNY)
Resmed Inc DRC (RSMDF) Resmed Inc DRC (RSMDF)
Terumo Corp ADR (TRUMY) Terumo Corp ADR (TRUMY)
Straumann Holding AG ADR (SAUHY) Straumann Holding AG ADR (SAUHY)
Sonova Holding AG (SONVY) Sonova Holding AG (SONVY)
Coloplast A (CLPBY) Coloplast A (CLPBY)
Fisher & Paykel Healthcare Ltd (FSPKF) Fisher & Paykel Healthcare Ltd (FSPKF)
Olympus Corp (OLYMY) Olympus Corp (OLYMY)
Demant A/S ADR (WILYY) Demant A/S ADR (WILYY)
Getinge Industrier AB (GNGBY) Getinge Industrier AB (GNGBY)
Sysmex Corp (SSMXY) Sysmex Corp (SSMXY)
ConvaTec Group plc ADR (CNVVY) ConvaTec Group plc ADR (CNVVY)
CochLear Ltd ADR (CHEOY) CochLear Ltd ADR (CHEOY)
Ansell Ltd ADR (ANSLY) Ansell Ltd ADR (ANSLY)
Carl Zeiss Meditec AG ADR (CZMWY) Carl Zeiss Meditec AG ADR (CZMWY)
Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY) Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY)
Elekta AB ADR (EKTAY) Elekta AB ADR (EKTAY)
Nihon Kohden Corp ADR (NHNKY) Nihon Kohden Corp ADR (NHNKY)
Top Glove Corporation Bhd ADR (TGLVY) Top Glove Corporation Bhd ADR (TGLVY)
Cyberdyne Inc ADR (CYBQY) Cyberdyne Inc ADR (CYBQY)
Paxman AB (PXMBF) Paxman AB (PXMBF)
Zomedica Corp (ZOMDF) Zomedica Corp (ZOMDF)